Wall Street Analysts Think Benitec Biopharma (BNTC) Could Surge 83.91%: Read This Before Placing a Bet

Group 1 - The core viewpoint is that Benitec Biopharma Limited (BNTC) has significant upside potential, with a mean price target of $25.71 indicating an 83.9$13.98 [1] - The mean estimate consists of seven short-term price targets with a standard deviation of $6.70, suggesting variability in analyst predictions; the lowest estimate is$17 (21.6% increase), while the highest is $35 (150.4% increase) [2] - Analysts show strong agreement on BNTC's ability to report better earnings than previously predicted, which supports the expectation of stock upside [4][11] Group 2 - The Zacks Consensus Estimate for BNTC has increased by 15.6% due to three upward revisions in earnings estimates over the last 30 days, with no negative revisions [12] - BNTC holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating strong potential for near-term upside [13] - While price targets may not be entirely reliable, the direction they imply appears to be a good guide for potential price movement [13]